Core Viewpoint - The global pharmaceutical market in Q3 2025 is experiencing significant volatility, with some sectors performing exceptionally well while others struggle. The focus is on identifying promising investment opportunities in the pharmaceutical industry, particularly in the areas of drug research and development outsourcing (CXO) and biotechnology funds in the US [2][3]. Summary by Sections 1. Key Directions to Watch - The pharmaceutical sector in A-shares and Hong Kong is primarily driven by companies providing research and production services to drug manufacturers, known as CXO. These companies are benefiting from a resurgence in demand for new drug development, leading to strong order volumes and stable profitability [3][4]. 2. Market Performance Overview - In Q3 2025, the A-share biotechnology index rose by 14%, matching the performance of the Shanghai Composite Index. Notably, the pharmaceutical research outsourcing sector surged by 48%, driven by robust order volumes and solid earnings [5][6]. - The Hong Kong pharmaceutical sector outperformed the broader market, with healthcare stocks rising by 41%, led by biotechnology and life sciences services, which saw increases of 54% and 51%, respectively [6][8]. - In contrast, US pharmaceutical stocks lagged, with the S&P 500 healthcare index only increasing by 2%, attributed to a decline in post-pandemic earnings and ongoing policy uncertainties [6][7]. 3. Long-term Market Trends - Over the past year, the Hong Kong pharmaceutical sector has seen a remarkable increase of over 100%, while A-shares have also experienced significant gains, particularly in the pharmaceutical research outsourcing segment, which rose by 111% [8][9]. - The A-share pharmaceutical market is showing a clear trend of divergence, with strong performers like CXO and innovative drugs thriving, while other sectors face challenges, including a projected revenue decline of 2% for 2024 [10][11]. 4. Investment Opportunities and Risks - The two resilient sectors in the A-share market are pharmaceutical research outsourcing and innovative drugs, both of which are experiencing improved revenue and profit margins due to increased demand from global pharmaceutical companies [12]. - Conversely, sectors such as vaccines, offline pharmacies, blood products, and medical devices are facing significant challenges, including intense competition and regulatory pressures [13][14]. 5. US Market Dynamics - The key driver for the US pharmaceutical market is the anticipated interest rate cuts by the Federal Reserve, which historically lead to positive performance in the biotechnology sector. Funds like IBB and XBI have already begun to outperform the broader market following these developments [17][18]. - Two leading companies in the US market, UnitedHealth and Novo Nordisk, are highlighted for their strong fundamentals and growth potential, particularly in the obesity treatment market [19][20]. 6. Conclusion - The current landscape of the global pharmaceutical market is characterized by a need for selective investment strategies, focusing on high-certainty opportunities in specific sectors such as CXO and biotechnology funds. External factors like Federal Reserve policies and US pharmaceutical regulations will significantly influence market dynamics [20].

来源：市场资讯 （来源：智远资讯） 【2025年9月24日，美国宾夕法尼亚州】方达控股与韩国GCCL宣布，于9月23日签署战略备忘录 （MOU），以加强双方在全球临床试验市场的影响力。GCCL是韩国领先的临床试验样本分析提供商， 方达控股可提供从临床前到临床服务一站式解决方案。此次合作旨在充分发挥双方服务与实验室网络优 势，提升在美国及亚太地区（APAC）的竞争力，推动双方共同发展。 在签约仪式上，两家公司重申了合作承诺，探讨了多项合作机会，包括在美国及亚太地区联合提供临床 试验服务、共同营销、项目支持计划、新业务机会的开发以及其他合作举措。 方达控股与GCCL将结合各自区域的专业优势和全球网络，共同执行临床试验项目，为全球客户提供更 加高效、差异化的服务。通过此次合作，方达将进一步加强其在亚太地区的临床试验支持体系，同时 GCCL也将持续拓展其全球服务能力。 方达控股高级副总裁张楠博士表示："通过本次战略合作，方达与GCCL建立合作关系，进一步加强其 在亚太市场的影响力，并与GCCL紧密合作，为全球临床试验提供更快捷、更高效的支持。通过结合双 方的专业知识与客户网络，我们将持续提升全球临床试验生态系统，为客 ...

Core Viewpoint - The report from Citi indicates that WuXi Biologics (02269) is expected to accelerate growth again between 2025 and 2027, with revenue forecasts raised by 0% to 4% and net profit forecasts increased by 0% to 7% [1] Group 1: Financial Projections - Gross margin is projected to improve from 28.5% in 2024 to 30.8% in 2027 [1] - The target price for the company has been raised from HKD 34.8 to HKD 42.6, maintaining an outperform rating [1] Group 2: Industry Insights - The profitability and valuation of the Contract Research Organization (CRO) industry are sensitive to changes in the funding environment [1] - A potential interest rate cut in the US in the second half of the year is expected to enhance market preference for the CRO sector [1] - Global biotech companies are anticipated to increase R&D investments in a more favorable funding environment, while pharmaceutical companies will also expand R&D spending to alleviate patent barrier pressures, benefiting WuXi Biologics [1]

Group 1 - The company reported a revenue of 2.701 billion yuan in H1 2025, representing a year-on-year increase of 62.2%, and an adjusted net profit (excluding interest income and expenses) of 733 million yuan, up 69.6% [1] - The total amount of uncompleted orders reached 1.329 billion yuan, a year-on-year increase of 57.9%, with North America accounting for over half of this total [1] - The company signed 37 new iCMC projects and won 13 iCMC projects in H1 2025, with a total of 563 clients, reflecting a 64% increase [1] Group 2 - The company plans to invest 1.56 billion yuan in capital expenditures in 2025, with total capital expenditures expected to exceed 7 billion yuan by 2029 to expand domestic and international production capacity [2] - The new production facility in Wuxi is fully operational, and the new park is expected to be operational by May 2025, with sufficient order reserves [2] - The company expects Non-GAAP net profits of 1.696 billion yuan, 2.199 billion yuan, and 2.908 billion yuan for 2025, 2026, and 2027 respectively, with corresponding PE ratios of 41, 32, and 24 times [3]

Summary of Prolo Pharmaceutical Conference Call Company Overview - Prolo Pharmaceutical is engaged in the CDMO (Contract Development and Manufacturing Organization) business, which is experiencing rapid growth due to capacity expansion and enhanced R&D capabilities. The company expects revenue growth to remain above 25% over the next three years, making it a core driver of performance [2][4][31]. Key Business Segments CDMO Business - The CDMO business is entering a phase of accelerated growth, supported by an increase in project numbers and commercial orders. Significant capital investments in advanced production facilities have been made, enhancing production efficiency and R&D capabilities [4][31]. - Revenue from the CDMO segment reached 1.884 billion yuan in 2024, with a compound annual growth rate (CAGR) exceeding 20% since 2020 [14]. API and Intermediate Business - Prolo has over 30 years of experience in the API (Active Pharmaceutical Ingredient) and intermediate business, with plans to add 30 to 50 new API products in the next three years. The company aims to expand into the medical beauty and cosmetics sectors [2][5]. - The company’s API projects include 116 ongoing projects, with 22 in the commercialization stage [20]. Formulation Business - The formulation segment has benefited from national procurement policies, leading to steady revenue growth of around 10% over the next three years. The company plans to develop 25 new formulation projects annually [6][30]. Financial Outlook - In 2025, Prolo's apparent revenue may be pressured by weak antibiotic demand and the clearing of raw material trading business, but profits are expected to remain stable or grow slightly. From 2026 onwards, revenue is projected to grow by about 10%, with profits increasing by over 20%, primarily driven by the CDMO business [7][32]. - The overall gross margin is expected to improve as the CDMO revenue share increases and cost-reduction measures are implemented [13][32]. Market Dynamics - The raw material and intermediate business is facing intense competition, but the company is diversifying its product matrix to mitigate cyclical impacts. The company is also leveraging advanced production capabilities to enhance competitiveness [8][26]. - In the veterinary medicine sector, Prolo's API business, particularly with florfenicol, is expected to benefit from a recovery in livestock farming and price stabilization [3][27][28]. Strategic Initiatives - Prolo's future strategy includes enriching its product matrix with new API products and expanding into high-margin markets such as medical beauty and cosmetics [29]. - The company has established a comprehensive supply chain for its formulation business, which includes over 120 formulation varieties across various therapeutic areas [30]. R&D and Innovation - Prolo is focusing on advanced research areas such as fluid chemistry, synthetic biology, and high-activity compounds, supported by a robust R&D team [17][18]. Conclusion - Prolo Pharmaceutical is positioned for significant growth in the coming years, driven by its CDMO business and strategic expansion into new markets. The company’s proactive approach to enhancing production capabilities and diversifying its product offerings is expected to yield positive financial results and improve overall profitability [2][32].

Summary of WuXi AppTec's Conference Call Company Overview - **Company**: WuXi AppTec - **Industry**: Contract Research, Development, and Manufacturing Organization (CRDMO) Key Points Financial Performance - WuXi AppTec's Q2 2025 results exceeded expectations, driven by the "Taizi" business, leading to an upward revision of the full-year revenue guidance to **42.5-43.5 billion CNY** from the previous **41.5-43 billion CNY** [2][3] - The company reported a profit growth rate that outpaced revenue growth, indicating strong operational efficiency [2][4] Business Segments and Growth Drivers - The "Taizi" business is a significant short-term growth driver, contributing to rapid revenue increases [2][4] - WuXi AppTec holds a strong position in the peptide CDMO sector, with solid growth in small molecule CDMO and drug discovery services [4][27] - The company has expanded its solid-phase synthesis reactor capacity to **41,000 liters** by 2024, enhancing its capabilities in the peptide market [4][28] Market Dynamics - The market's valuation concerns regarding the biomanufacturing sector are diminishing, particularly with the U.S. Congress not passing the biomanufacturing safety bill [6][19] - The anticipated U.S. interest rate cuts and a surge in domestic innovative drug BD transactions are expected to boost the CXO industry's demand for R&D outsourcing [5][12] Globalization and Risk Management - WuXi AppTec has established a global production footprint, including bases in Singapore and Europe, to mitigate potential trade restrictions and enhance supply chain resilience [8][9] - The company's integrated CRDMO model allows seamless transitions from early drug development to commercial production, improving project timelines and client responsiveness [23][25] Order Book and Future Outlook - As of Q2 2025, new orders have maintained a rapid growth rate of nearly **40%**, laying a solid foundation for future growth [7][20] - The company is expected to see continued growth in its small molecule and peptide segments, with projections indicating that peptide business growth could exceed **80%** in 2025 [28] Competitive Advantages - WuXi AppTec's competitive edge lies in its integrated CRDMO model, cost advantages, and compliance capabilities, which are difficult for competitors to replicate [6][24] - The company has a strong international presence that aligns with the global trend of innovative drug development, helping to offset geopolitical risks [9][13] Challenges and Market Sentiment - Current market concerns include geopolitical risks affecting international competitiveness and the sufficiency of future growth drivers [11][19] - Despite these challenges, WuXi AppTec's proactive international strategy and ability to capture emerging R&D trends position it favorably for sustained growth [11][19] Investment Considerations - The overall investment outlook for WuXi AppTec remains positive, with expectations of strong growth driven by its core business segments and favorable market conditions [31] - The company is recommended for its strong growth potential and relatively low valuation compared to peers [31] Conclusion WuXi AppTec is well-positioned in the CRDMO industry, with robust growth prospects driven by its innovative business model, global expansion, and strong order book. The company is expected to navigate current market challenges effectively, making it a compelling investment opportunity.

Core Viewpoint - Guosen Securities has given WuXi AppTec (603259.SH, latest price: 98.85 CNY) an "outperform" rating due to strong order growth and an upward revision of the annual performance guidance [2] Group 1: Company Performance - The company has experienced robust order growth, prompting a proactive adjustment of its annual performance guidance [2] - In the chemical business, the small molecule CRDMO has shown efficient transformation, while the TIDES business has made significant contributions [2] - The testing and biological services segment has maintained a steady performance [2] Group 2: Market Dynamics - The company has deepened its global customer structure, with the U.S. market continuing to show leading growth rates [2]

Group 1 - The company plans to issue 73.8 million H-shares at a price of HKD 104.27 per share, aiming to raise approximately HKD 7.65 billion, with about 90% allocated for global expansion and capacity building, and 10% for general operational funds [1] - The company reported a revenue of CNY 20.799 billion for the first half of 2025, representing a year-on-year growth of 20.64%, with net profit attributable to shareholders reaching CNY 8.56 billion, a significant increase of 101.92% [1] - The company announced its first-ever interim dividend of approximately CNY 1 billion, distributing CNY 3.5 per 10 shares, with total cash dividends and share buybacks since 2025 reaching nearly CNY 7 billion [2] Group 2 - The company has increased its full-year performance guidance, projecting a revenue growth rate for its ongoing business from 10%-15% to 13%-17%, and overall revenue expectations adjusted from CNY 41.5 billion-43 billion to CNY 42.5 billion-43.5 billion [2] - As of June 30, 2025, the company reported a backlog of orders for ongoing business amounting to CNY 56.69 billion, reflecting a year-on-year growth of 37.2% [2] - Revenue from U.S. clients reached CNY 14.03 billion, up 38.4% year-on-year, while revenue from European clients was CNY 2.33 billion, growing by 9.2% [2]

Investment Rating - The report maintains a "Recommended" rating for WuXi AppTec, indicating a positive outlook for the company's stock performance relative to the benchmark index [6]. Core Insights - WuXi AppTec's TIDES business continues to experience high growth, leading to an upward revision of the full-year performance guidance. The company expects a revenue growth rate of 13-17% for its continuing operations in 2025, up from the previous estimate of 10-15% [6]. - The company reported a significant increase in revenue and net profit for the first half of 2025, with total revenue reaching RMB 20.8 billion, a year-on-year increase of 20.6%, and net profit attributable to shareholders rising by 101.9% to RMB 8.56 billion [6]. - The report highlights strong performance in the chemical business, with a revenue increase of 33.5% year-on-year, and a remarkable growth of 141.6% in the TIDES business [6]. Financial Forecast Summary - **Revenue Forecast**: Projected revenues for 2024A, 2025E, 2026E, and 2027E are RMB 39,241.43 million, RMB 44,117.35 million, RMB 50,436.29 million, and RMB 57,615.13 million respectively, with growth rates of -2.73%, 12.43%, 14.32%, and 14.23% [2][8]. - **Net Profit Forecast**: Expected net profits for the same years are RMB 9,450.31 million, RMB 14,201.96 million, RMB 14,954.50 million, and RMB 18,240.90 million, reflecting growth rates of -1.63%, 50.28%, 5.30%, and 21.98% [2][8]. - **Key Ratios**: The projected PE ratios for 2025E, 2026E, and 2027E are 19.99, 18.99, and 15.56 respectively, indicating a favorable valuation trend [2][8]. Business Performance Highlights - The company reported a backlog of orders amounting to RMB 56.69 billion, a year-on-year increase of 37.2%, indicating strong future revenue potential [6]. - Revenue from U.S. clients reached RMB 14.03 billion, a 38.4% increase year-on-year, while revenue from European clients grew by 9.2% to RMB 2.33 billion [6]. - The report notes that the TIDES business is expected to continue driving overall performance, supported by robust demand and a solid order backlog [6].

Core Viewpoint - WuXi AppTec reported strong financial results for 1H25, exceeding expectations, with significant revenue and profit growth, prompting an upward revision of full-year guidance for 2025 [1][2]. Financial Performance - Revenue increased by 20.6% YoY, with continuing operations growing by 24.2% YoY [1] - Adjusted non-IFRS net profit surged by 44.4% YoY [1] - Revenue from continuing operations and adjusted non-IFRS net profit accounted for 47.5% and 54.4% of full-year forecasts, respectively, both higher than historical ranges [1] Operational Highlights - Management raised full-year guidance for 2025, expecting revenue growth for continuing operations to be between 13-17%, up from the previous 10-15% [2] - The demand for late-stage clinical and commercial manufacturing has been a key growth driver for the global CXO industry post-COVID [2] - TIDES revenue surged by 141.6% YoY due to faster-than-expected manufacturing capacity ramp-up [2] - Revenue from small molecule D&M grew by 17.5% YoY, indicating a recovery from previous negative growth [2] Capacity Expansion - WuXi AppTec's backlog grew by 37.2% YoY, with TIDES backlog increasing by 48.8% YoY [3] - Plans to increase peptide capacity to over 100k liters by the end of 2025 to meet demand [3] - Ongoing capacity expansion at multiple sites, including locations in China, Singapore, the US, and Switzerland [3] - Capex target reaffirmed at RMB7-8 billion for 2025, with potential increases anticipated in the coming years [3] Early-stage R&D Insights - Revenue from early-stage R&D services showed sequential improvements but a meaningful recovery is expected to take time [4] - Early-stage R&D services contribute approximately 30% of the company's total revenue [4] Investment Outlook - Target price raised from RMB77.22 to RMB116.56 based on upgraded guidance and improved macro environment [5] - Expected revenue growth from continuing operations of 16.0%/15.9%/15.8% YoY and adjusted non-IFRS net profit growth of 16.2%/17.6%/16.4% YoY for 2025E/26E/27E, respectively [5]